Others have successfully used the same approach, for example, Binatrafusp alfa (57) and SHR-1701 (58) are anti-PD-L1 C-terminally fused TβRII-ED bifunctional fusion proteins, that have both been evaluated in clinical trials either as mono- or combination therapy for the treatment of several types of cancer (59–65). This evidence concerns the gene TGFBR2 and cancer.